260 related articles for article (PubMed ID: 19888808)
1. Susceptibility testing of amorolfine, bifonazole and ciclopiroxolamine against Trichophyton rubrum in an in vitro model of dermatophyte nail infection.
Schaller M; Borelli C; Berger U; Walker B; Schmidt S; Weindl G; Jäckel A
Med Mycol; 2009 Nov; 47(7):753-8. PubMed ID: 19888808
[TBL] [Abstract][Full Text] [Related]
2. Sporicidal effect of amorolfine and other antimycotics used in the therapy of fungal nail infections.
Seidl HP; Jäckel A; Müller J; Schaller M; Borelli C; Polak A
Mycoses; 2015 Oct; 58(10):610-9. PubMed ID: 26334024
[TBL] [Abstract][Full Text] [Related]
3. Antifungal drug response in an in vitro model of dermatophyte nail infection.
Osborne CS; Leitner I; Favre B; Ryder NS
Med Mycol; 2004 Apr; 42(2):159-63. PubMed ID: 15124869
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported outcomes from two randomised studies comparing once-weekly application of amorolfine 5% nail lacquer to other methods of topical treatment in distal and lateral subungual onychomycosis.
Schaller M; Sigurgeirsson B; Sarkany M
Mycoses; 2017 Dec; 60(12):800-807. PubMed ID: 28925059
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, randomized, open-label, controlled study comparing the efficacy, safety and cost-effectiveness of a sequential therapy with RV4104A ointment, ciclopiroxolamine cream and ciclopirox film-forming solution with amorolfine nail lacquer alone in dermatophytic onychomycosis.
Paul C; Coustou D; Lahfa M; Bulai-Livideanu C; Doss N; Mokthar I; Turki H; Nouira R; Fazaa B; Ben Osman A; Zourabichvili O; Cazeau C; Coubetergues H; Picot S; Bienvenu AL; Voisard JJ
Dermatology; 2013; 227(2):157-64. PubMed ID: 24051622
[TBL] [Abstract][Full Text] [Related]
6. The low keratin affinity of efinaconazole contributes to its nail penetration and fungicidal activity in topical onychomycosis treatment.
Sugiura K; Sugimoto N; Hosaka S; Katafuchi-Nagashima M; Arakawa Y; Tatsumi Y; Jo Siu W; Pillai R
Antimicrob Agents Chemother; 2014 Jul; 58(7):3837-42. PubMed ID: 24752277
[TBL] [Abstract][Full Text] [Related]
7. Action mechanisms of modern antifungal agents and resulting problems in the management of onychomycosis.
Seebacher C
Mycoses; 2003 Dec; 46(11-12):506-10. PubMed ID: 14641625
[TBL] [Abstract][Full Text] [Related]
8. Characterization of Antifungal Activity and Nail Penetration of ME1111, a New Antifungal Agent for Topical Treatment of Onychomycosis.
Tabata Y; Takei-Masuda N; Kubota N; Takahata S; Ohyama M; Kaneda K; Iida M; Maebashi K
Antimicrob Agents Chemother; 2016 Feb; 60(2):1035-9. PubMed ID: 26643333
[TBL] [Abstract][Full Text] [Related]
9. In vitro susceptibility testing of amorolfine in pathogenic fungi isolated from dermatomycosis patients in China.
Li RY; Wan Z; Wang AP; Shen YN; Lu CM; Li M; Xi LY; Liu WD; Zeng FQ
Mycoses; 2004 Oct; 47(9-10):402-6. PubMed ID: 15504124
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of 5% amorolfine nail lacquer in Neoscytalidium dimidiatum onychomycosis.
Bunyaratavej S; Leeyaphan C; Rujitharanawong C; Surawan TM; Muanprasat C; Matthapan L
J Dermatolog Treat; 2016 Aug; 27(4):359-63. PubMed ID: 26471716
[TBL] [Abstract][Full Text] [Related]
11. Application of cosmetic nail varnish does not affect the antifungal efficacy of amorolfine 5% nail lacquer in the treatment of distal subungual toenail onychomycosis: results of a randomised active-controlled study and in vitro assays.
Sigurgeirsson B; Ghannoum MA; Osman-Ponchet H; Kerrouche N; Sidou F
Mycoses; 2016 May; 59(5):319-26. PubMed ID: 26867498
[TBL] [Abstract][Full Text] [Related]
12. A randomized comparison of nail surface remanence of three nail lacquers, containing amorolfine 5%, ciclopirox 8% or tioconazole 28%, in healthy volunteers.
Sidou F; Soto P
Int J Tissue React; 2004; 26(1-2):17-24. PubMed ID: 15573688
[TBL] [Abstract][Full Text] [Related]
13. Treatment costs of three nail lacquers used in onychomycosis.
Marty JP; Lambert J; Jäckel A; Adjadj L
J Dermatolog Treat; 2005; 16(5-6):299-307. PubMed ID: 16428149
[TBL] [Abstract][Full Text] [Related]
14. Agar sublimation test for the in vitro determination of the antifungal activity of morpholine derivatives.
Polak A; Jäckel A; Noack A; Kappe R
Mycoses; 2004 Jun; 47(5-6):184-92. PubMed ID: 15189181
[TBL] [Abstract][Full Text] [Related]
15. Infected nail plate model made of human hair keratin for evaluating the efficacy of different topical antifungal formulations against Trichophyton rubrum in vitro.
Lusiana ; Reichl S; Müller-Goymann CC
Eur J Pharm Biopharm; 2013 Aug; 84(3):599-605. PubMed ID: 23419812
[TBL] [Abstract][Full Text] [Related]
16. Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections.
Haria M; Bryson HM
Drugs; 1995 Jan; 49(1):103-20. PubMed ID: 7705210
[TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibility of dermatomycoses agents to six antifungal drugs and evaluation by fractional inhibitory concentration index of combined effects of amorolfine and itraconazole in dermatophytes.
Tamura T; Asahara M; Yamamoto M; Yamaura M; Matsumura M; Goto K; Rezaei-Matehkolaei A; Mirhendi H; Makimura M; Makimura K
Microbiol Immunol; 2014 Jan; 58(1):1-8. PubMed ID: 24215461
[TBL] [Abstract][Full Text] [Related]
18. A pilot, layerwise, ex vivo evaluation of the antifungal efficacy of amorolfine 5% nail lacquer vs other topical antifungal nail formulations in healthy toenails.
Ghannoum M; Long L; Kunze G; Sarkany M; Osman-Ponchet H
Mycoses; 2019 Jun; 62(6):494-501. PubMed ID: 30667544
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the antifungal efficacy of terbinafine hydrochloride and ciclopirox olamine containing formulations against the dermatophyte Trichophyton rubrum in an infected nail plate model.
Täuber A; Müller-Goymann CC
Mol Pharm; 2014 Jul; 11(7):1991-6. PubMed ID: 24490976
[TBL] [Abstract][Full Text] [Related]
20. Transungual delivery of efinaconazole: its deposition in the nail of onychomycosis patients and in vitro fungicidal activity in human nails.
Sakamoto M; Sugimoto N; Kawabata H; Yamakawa E; Kodera N; Pillai R; Tatsumi Y
J Drugs Dermatol; 2014 Nov; 13(11):1388-92. PubMed ID: 25607707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
